SGO 2022 Annual Meeting Cervical Cancer Studies

As an ovarian cancer survivor, I normally concentrate my posts on ovarian cancer but there were a number of very interesting  cervical cancer and endometrial cancer studies/results presented at the SGO annual meeting. 

This post will focus on the cervical cancer sessions.

Scientific Plenary II: Building Bridges - Pioneering Protocols and Scientific Progress

Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer -  Monk

 

Pembro is not statistically better, but numerically better on PROs for metastatic/recurrent cervical cancer. #keynote826 #SGOMtg #cervixcancer pic.twitter.com/Bhs5rqA84r

— Erin Stevens (@erinstevensmd) March 18, 2022

 

Safety and Immunogenicity of Anti PD-L1 (Atezolizumab) Given as an Immune Primer or Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer: an NRG Oncology Trial –  J. Mayadev 

 

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: a Cost-Effectiveness Analysis –  D. Barrington  

 

 

 

 

Scientific Plenary III: Novel Therapeutics: The Expanding Toolbox

 

Efficacy and Safety of Serplulimab (an anti-PD-1 antibody) Combined with Albumin-Bound Paclitaxel in Patients with Advanced Cervical Cancer who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy – J. An

 

 

 

 

#SGOmtg Serplulimab (an anti-PD-1 antibody) Combined with Albumin-Bound Paclitaxel in Patients w/ Advanced Cervical Cancer who Have progressive disease Dr An
57% had ORR , mPFS was 5.7 mo , mOS 15.5 mo
Manageable toxicity #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

 

 

Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in Previously Treated Recurrent or Metastatic (R/M) Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Trial – Speaker: X. Wu

 

#SGOmtg Efficacy and Safety of Cadonilimab, an Anti-PD-1/CTLA4 Bi-Specific Antibody, in
Previously Treated R/M Cervical Cancer: X. Wu
ORR 33% - 12 patients had a CR and 21 PR
Responded regardless of PDL1 status #gyncsm

— Dee Sparacio (@womenofteal) March 19, 2022

Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis – R. Ramirez I recalled the initial discussion/ debate on minimally invasive hysterectomy vs open surgery at an ASCO meeting a few years ago. Minimal invasive hysterectomy surgery should not be used.

 

 

 

 

The next post will report on some endometrial cancer  studies

Dee 

Every Day is a Blessing!